Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Hang Quach

27PUBLICATIONS

117CO-AUTHORS

Medical bacteriologyGene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsMedical mycology

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (27)

Sort by Publication Date:

|May 05, 2026

Infections in patients receiving daratumumab for newly diagnosed multiple myeloma: a pooled analysis of MAIA and ALCYONE.

|Mar 02, 2026

Efficacy and Safety of Belantamab Mafodotin with Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: The DREAMM-6 Arm B Trial.

Rakesh Popat, Bradley Augustson, Paul Cannell

|Dec 27, 2025

Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO.

Gurdeep Parmar, Marcelo Capra, Fernanda Seguro

|Aug 28, 2025

Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial.

Michelle K Yong, Karin Thursky, Megan Crane

|Aug 05, 2025

Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials.

María-Victoria Mateos, Suzanne Trudel, Hang Quach

|May 10, 2025

EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma.

Sagar Lonial, Meletios A Dimopoulos, Jesus G Berdeja

Pageof 5

Frequent Collaborators

6 joint publications

Maria-Victoria Mateos

5 joint publications

Andrew Spencer

5 joint publications

Shaji Kumar

5 joint publications

Nizar J Bahlis

4 joint publications

P Joy Ho

4 joint publications

Simon James Harrison

3 joint publications

Philippe Moreau

3 joint publications

Zoe McQuilten

3 joint publications

Robert Z Orlowski

3 joint publications

Elizabeth Moore

Frequent Collaborators

6 joint publications

Maria-Victoria Mateos

5 joint publications

Andrew Spencer

5 joint publications

Shaji Kumar

5 joint publications

Nizar J Bahlis

Top Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on : Jul 15, 2015

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on : May 15, 2019

Studying Interactions between Myeloid Cells and CAR T Cells <em>In Vitro</em> and <em>In Vivo</em>

Studying Interactions between Myeloid Cells and CAR T Cells <em>In Vitro</em> and <em>In Vivo</em>

Published on : Jul 25, 2025

See more related videos

Top Related Videos

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on : Jul 15, 2015

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on : May 15, 2019

Studying Interactions between Myeloid Cells and CAR T Cells <em>In Vitro</em> and <em>In Vivo</em>

Studying Interactions between Myeloid Cells and CAR T Cells <em>In Vitro</em> and <em>In Vivo</em>

Published on : Jul 25, 2025

See more related videos